Antiplatelet Drugs Market Overview

The report is titled as ‘Antiplatelet Drugs Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the antiplatelet drugs market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Antiplatelet drugs market is expected to grow with significant rate in the near future.

The global antiplatelet drugs market in 2020 is estimated for more than US$ 1.7 Bn and expected to reach a value of US$ 2.4 Bn by 2028 with a significant CAGR of 7.6%.

Antiplatelet Drugs Market Definition

Antiplatelet drugs are endorsed to people with a background marked by heart attacks and these medications help in decreasing reoccurrence of heart attacks. A portion of the antiplatelet drugs incorporate, ibuprofen, clopidogrel, prasugrel, and ticagrelor. Aspirin is suggested for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed alongside one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients experiencing ACS and for those experiencing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor help in anticipating atherothrombotic events in adult patients with ACS, and the individuals who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Antiplatelet Drugs Market Dynamics

Increasing prevalence of cardiovascular issue, developing geriatric populace, and stationary way of life are a portion of the main considerations driving the global antiplatelet drugs market development. Cardiovascular diseases are the central reason for death in the developed and developing economies around the globe. As per a report by Centers for Disease Control and Prevention (CDC), 2015, around 800,000 individuals in the U.S. die yearly because of stroke and other cardiovascular diseases. A portion of the normal cardiovascular sicknesses incorporate, rheumatic coronary illness, hypertensive coronary illness, incendiary coronary illness, ischemic coronary illness, and cerebrovascular coronary illness.

Antiplatelet Drugs Market Segmentation

The antiplatelet drugs market is segmented on the basis of drug type, application, end user, and by region.

By Drug Type

•    Aspirin

•    Clopidogrel

•    Ticagrelor

•    Prasugrel

•    Dipyridamole

•    Ticlopidine

•    Abciximab

•    Tirofiban

•    Others

By Application

•    Myocardial Infraction

•    Percutaneous Coronary Interventions

•    Angioplasty

•    Arterial Thrombosis

•    Dental surgeries

•    Others

By End User

•    Hospitals

•    Clinic

•    Emergency Service Centers

•    Ambulatory Surgical Centers

•    Others

Antiplatelet Drugs Market Key Players

Some of the key participating players in antiplatelet drugs market are

•    AstraZeneca Inc.

•    The Medicines Company

•    Portola Pharmaceuticals, Inc.

•    Bayer Pharmaceuticals

•    Bristol-Myers Squibb Company

•    Boehringer Ingelheim Pharmaceuticals Inc.

•    Altimed Pharma Inc.

•    Dominion Pharmacal

•    Alta Laboratories Ltd.

•    Novacap

•    Shandong Xinhua Pharmaceutical

•    Nanjing Pharmaceutical Factory

•    Sanis Health Inc.

•    Syntex Inc.

•    Hoffmann La Roche

•    Teva Pharmaceutical

•    Sandoz Canada Incorporated

•    Pharmascience Inc.

•    Nu Pharm Inc.

•    Mylan Pharmaceuticals

Antiplatelet Drugs Market Regional Analysis and Overview

North America and Europe antiplatelet drugs market are relied upon to predict critical development by 2026 as cardiovascular sicknesses are the chief reason for death in these districts. As indicated by an European Heart Journal 2014 examination, Coronary Heart Diseases (CHD), especially Myocardial Infarction (MI), is in charge of around 1.8 million passings in Europe, every year.

Expanding pervasiveness of cardiovascular diseases in Asia Pacific is relied upon to fuel the antiplatelet market development in the region. As indicated by the American Heart Association, in 2011, 17,050 passings among Asian and Pacific Islanders were because of cardiovascular diseases; 7,828 because of coronary illness; and 2,476 because of myocardial localized necrosis.

In any case, as per the American Heart Journal 2015 database, individuals in Asia Pacific are susceptible to antithrombotics or fibrinolytics and to be related with a higher bleeding risk amid the board of ischemic heart diseases and antithrombotic therapy. For example, excessive bleeding risk with standard dosages of new P2Y12 inhibitors is seen in patients in Asia Pacific, particularly in its eastern region. As indicated by the Circulation Journal 2014 report, for Prasugrel, a lower maintenance dose of 3.75 mg day by day was utilized in clinical studies and approved for Japanese patients. The lower body load of patients in Asia Pacific, fixed dose routine of most antiplatelet drugs, and distinctive hereditary foundations are the potential variables in charge of expanded danger of dying. Thusly, bleeding is seen as an essential worry for choosing antiplatelet drugs for patients in Asia Pacific.

MMC Overview on Antiplatelet Drugs Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Antiplatelet Drugs market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Antiplatelet Drugs 

•    Advantages of Antiplatelet Drugs over other modalities

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Antiplatelet Drugs Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Antiplatelet Drugs Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Antiplatelet Drugs Market Snapshot

2.4.    Global Antiplatelet Drugs Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Antiplatelet Drugs Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Antiplatelet Drugs Market, By Drug Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Drug Type

3.1.2.    BPS Analysis, By Drug Type

3.2.    Market Revenue (US$Mn) Forecast, By Drug Type

3.2.1.    Aspirin

3.2.2.    Clopidogrel

3.2.3.    Ticagrelor

3.2.4.    Prasugrel

3.2.5.    Dipyridamole

3.2.6.    Ticlopidine

3.2.7.    Abciximab

3.2.8.    Tirofiban

3.2.9.    Others

3.3.    Global Antiplatelet Drugs Market Attractiveness Index, By Drug Type

4.    Global Antiplatelet Drugs Market, By Application

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Application

4.1.2.    BPS Analysis, By Application

4.2.    Market Revenue (US$Mn) Forecast, By Application

4.2.1.    Myocardial Infraction

4.2.2.    Percutaneous Coronary Interventions

4.2.3.    Angioplasty

4.2.4.    Arterial Thrombosis

4.2.5.    Dental surgeries

4.2.6.    Others

4.3.    Global Antiplatelet Drugs Market Attractiveness Index, By Application

5.    Global Antiplatelet Drugs Market, By End User

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By End User

5.1.2.    BPS Analysis, By End User

5.2.    Market Revenue (US$Mn) Forecast, By End User

5.2.1.    Hospitals

5.2.2.    Clinic

5.2.3.    Emergency Service Centers

5.2.4.    Ambulatory Surgical Centers

5.2.5.    Others

5.3.    Global Antiplatelet Drugs Market Attractiveness Index, By End User

6.    Global Antiplatelet Drugs Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Antiplatelet Drugs Market Attractiveness Index, By Region

7.    North America Antiplatelet Drugs Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Antiplatelet Drugs Market

7.2.2.    Canada Antiplatelet Drugs Market

7.3.    North America Antiplatelet Drugs Market, By Drug Type

7.3.1.    Aspirin

7.3.2.    Clopidogrel

7.3.3.    Ticagrelor

7.3.4.    Prasugrel

7.3.5.    Dipyridamole

7.3.6.    Ticlopidine

7.3.7.    Abciximab

7.3.8.    Tirofiban

7.3.9.    Others

7.4.    North America Antiplatelet Drugs Market, By Application

7.4.1.    Myocardial Infraction

7.4.2.    Percutaneous Coronary Interventions

7.4.3.    Angioplasty

7.4.4.    Arterial Thrombosis

7.4.5.    Dental surgeries

7.4.6.    Others

7.5.    North America Antiplatelet Drugs Market, By End User

7.5.1.    Hospitals

7.5.2.    Clinic

7.5.3.    Emergency Service Centers

7.5.4.    Ambulatory Surgical Centers

7.5.5.    Others

7.6.    North America Antiplatelet Drugs Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Drug Type

7.6.3.    By Application

7.6.4.    By End User

8.    Latin America Antiplatelet Drugs Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Antiplatelet Drugs Market

8.2.2.    Mexico Antiplatelet Drugs Market

8.2.3.    Argentina Antiplatelet Drugs Market

8.2.4.    Rest of Latin America Antiplatelet Drugs Market

8.3.    Latin America Antiplatelet Drugs Market, By Drug Type

8.3.1.    Aspirin

8.3.2.    Clopidogrel

8.3.3.    Ticagrelor

8.3.4.    Prasugrel

8.3.5.    Dipyridamole

8.3.6.    Ticlopidine

8.3.7.    Abciximab

8.3.8.    Tirofiban

8.3.9.    Others

8.4.    Latin America Antiplatelet Drugs Market, By Application

8.4.1.    Myocardial Infraction

8.4.2.    Percutaneous Coronary Interventions

8.4.3.    Angioplasty

8.4.4.    Arterial Thrombosis

8.4.5.    Dental surgeries

8.4.6.    Others

8.5.    Latin America Antiplatelet Drugs Market, By End User

8.5.1.    Hospitals

8.5.2.    Clinic

8.5.3.    Emergency Service Centers

8.5.4.    Ambulatory Surgical Centers

8.5.5.    Others

8.6.    Latin America Antiplatelet Drugs Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Drug Type

8.6.3.    By Application

8.6.4.    By End User

9.    Europe Antiplatelet Drugs Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Antiplatelet Drugs Market

9.2.2.    Germany Antiplatelet Drugs Market

9.2.3.    Italy Antiplatelet Drugs Market

9.2.4.    France Antiplatelet Drugs Market

9.2.5.    Spain Antiplatelet Drugs Market

9.2.6.    Russia Antiplatelet Drugs Market

9.2.7.    Poland Antiplatelet Drugs Market

9.2.8.    BENELUX Antiplatelet Drugs Market

9.2.9.    NORDIC Antiplatelet Drugs Market

9.2.10.    Rest of Europe Antiplatelet Drugs Market

9.3.    Europe Antiplatelet Drugs Market, By Drug Type

9.3.1.    Aspirin

9.3.2.    Clopidogrel

9.3.3.    Ticagrelor

9.3.4.    Prasugrel

9.3.5.    Dipyridamole

9.3.6.    Ticlopidine

9.3.7.    Abciximab

9.3.8.    Tirofiban

9.3.9.    Others

9.4.    Europe Antiplatelet Drugs Market, By Application

9.4.1.    Myocardial Infraction

9.4.2.    Percutaneous Coronary Interventions

9.4.3.    Angioplasty

9.4.4.    Arterial Thrombosis

9.4.5.    Dental surgeries

9.4.6.    Others

9.5.    Europe Antiplatelet Drugs Market, By End User

9.5.1.    Hospitals

9.5.2.    Clinic

9.5.3.    Emergency Service Centers

9.5.4.    Ambulatory Surgical Centers

9.5.5.    Others

9.6.    Europe Antiplatelet Drugs Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Drug Type

9.6.3.    By Application

9.6.4.    By End User

10.    Asia Pacific Antiplatelet Drugs Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Antiplatelet Drugs Market

10.2.2.    India Antiplatelet Drugs Market

10.2.3.    Japan Antiplatelet Drugs Market

10.2.4.    Australia and New Zealand Antiplatelet Drugs Market

10.2.5.    South Korea Antiplatelet Drugs Market

10.2.6.    ASEAN Antiplatelet Drugs Market

10.2.7.    Rest of Asia Pacific Antiplatelet Drugs Market

10.3.    Asia Pacific Antiplatelet Drugs Market, By Drug Type

10.3.1.    Aspirin

10.3.2.    Clopidogrel

10.3.3.    Ticagrelor

10.3.4.    Prasugrel

10.3.5.    Dipyridamole

10.3.6.    Ticlopidine

10.3.7.    Abciximab

10.3.8.    Tirofiban

10.3.9.    Others

10.4.    Asia Pacific Antiplatelet Drugs Market, By Application

10.4.1.    Myocardial Infraction

10.4.2.    Percutaneous Coronary Interventions

10.4.3.    Angioplasty

10.4.4.    Arterial Thrombosis

10.4.5.    Dental surgeries

10.4.6.    Others

10.5.    Asia Pacific Antiplatelet Drugs Market, By End User

10.5.1.    Hospitals

10.5.2.    Clinic

10.5.3.    Emergency Service Centers

10.5.4.    Ambulatory Surgical Centers

10.5.5.    Others

10.6.    Asia Pacific Antiplatelet Drugs Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Drug Type

10.6.3.    By Application

10.6.4.    By End User

11.    Middle East Antiplatelet Drugs Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Antiplatelet Drugs Market

11.2.2.    Israel Antiplatelet Drugs Market

11.2.3.    Oman Antiplatelet Drugs Market

11.2.4.    Rest of Middle East Antiplatelet Drugs Market

11.3.    Middle East Antiplatelet Drugs Market, By Drug Type

11.3.1.    Aspirin

11.3.2.    Clopidogrel

11.3.3.    Ticagrelor

11.3.4.    Prasugrel

11.3.5.    Dipyridamole

11.3.6.    Ticlopidine

11.3.7.    Abciximab

11.3.8.    Tirofiban

11.3.9.    Others

11.4.    Middle East Antiplatelet Drugs Market, By Application

11.4.1.    Myocardial Infraction

11.4.2.    Percutaneous Coronary Interventions

11.4.3.    Angioplasty

11.4.4.    Arterial Thrombosis

11.4.5.    Dental surgeries

11.4.6.    Others

11.5.    Middle East Antiplatelet Drugs Market, By End User

11.5.1.    Hospitals

11.5.2.    Clinic

11.5.3.    Emergency Service Centers

11.5.4.    Ambulatory Surgical Centers

11.5.5.    Others

11.6.    Middle East Antiplatelet Drugs Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Drug Type

11.6.3.    By Application

11.6.4.    By End User

12.    Africa Antiplatelet Drugs Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Antiplatelet Drugs Market

12.2.2.    Egypt Antiplatelet Drugs Market

12.2.3.    North Africa Antiplatelet Drugs Market

12.2.4.    Rest of Africa Antiplatelet Drugs Market

12.3.    Africa Antiplatelet Drugs Market, By Drug Type

12.3.1.    Aspirin

12.3.2.    Clopidogrel

12.3.3.    Ticagrelor

12.3.4.    Prasugrel

12.3.5.    Dipyridamole

12.3.6.    Ticlopidine

12.3.7.    Abciximab

12.3.8.    Tirofiban

12.3.9.    Others

12.4.    Africa Antiplatelet Drugs Market, By Application

12.4.1.    Myocardial Infraction

12.4.2.    Percutaneous Coronary Interventions

12.4.3.    Angioplasty

12.4.4.    Arterial Thrombosis

12.4.5.    Dental surgeries

12.4.6.    Others

12.5.    Africa Antiplatelet Drugs Market, By End User

12.5.1.    Hospitals

12.5.2.    Clinic

12.5.3.    Emergency Service Centers

12.5.4.    Ambulatory Surgical Centers

12.5.5.    Others

12.6.    Africa Antiplatelet Drugs Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Drug Type

12.6.3.    By Application

12.6.4.    By End User

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    AstraZeneca PLC

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    The Medicines Company

14.3.3.    Portola Pharmaceuticals, Inc.

14.3.4.    Bayer Pharmaceuticals

14.3.5.    Bristol-Myers Squibb Company

14.3.6.    Boehringer Ingelheim Pharmaceuticals Inc.

14.3.7.    Altimed Pharma Inc.

14.3.8.    Dominion Pharmacal

14.3.9.    Alta Laboratories Ltd.

14.3.10.    Novacap

14.3.11.    Shandong Xinhua Pharmaceutical

14.3.12.    Nanjing Pharmaceutical Factory

14.3.13.    Sanis Health Inc

14.3.14.    Syntex Inc.

14.3.15.    Hoffmann La Roche

14.3.16.    Teva Pharmaceutical

14.3.17.    Sandoz Canada Incorporated

14.3.18.    Pharmascience Inc.

14.3.19.    Nu Pharm Inc.

14.3.20.    Mylan Pharmaceuticals

15.    Acronyms